InnoCan Pharma (TSE:INNO) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Innocan Pharma has reported positive outcomes from a long-term compassionate therapy study where dogs with osteoarthritis experienced significant pain relief and mobility improvement after receiving liposomal-CBD (LPT-CBD) injections. The therapy could offer a non-opioid alternative for chronic pain management in animals, and potentially humans, with sustained effects lasting several weeks per dose.
For further insights into TSE:INNO stock, check out TipRanks’ Stock Analysis page.